Showing results (1-10 of 57) with videos related to
Sort By:
Pageof 6
Current Opinion in Pharmacology|September 29, 2005
Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strengthPaul J KostenuikEndocrine Reviews|December 7, 2007
Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and diseaseAnn E Kearns, Sundeep Khosla, Paul J KostenuikCurrent Osteoporosis Reports|June 8, 2023
Advances in Osteoporosis Therapy: Focus on Osteoanabolic Agents, Secondary Fracture Prevention, and Perioperative Bone HealthPaul J Kostenuik, Neil Binkley, Paul A AndersonClinical Therapeutics|March 24, 2012
Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical dataDavid W Dempster, Cheryl L Lambing, Paul J Kostenuik, et al.Advances in Experimental Medicine and Biology|October 31, 2007
RANKL inhibition: from mice to men (and women)Marina Stolina, Paul J Kostenuik, William C Dougall, et al.Bone|June 26, 2007
Local delivery of osteoprotegerin inhibits mechanically mediated bone modeling in orthodontic tooth movementMatthew D Dunn, Chan Ho Park, Paul J Kostenuik, et al.Calcified Tissue International|March 7, 2016
Influence of Fatigue Loading and Bone Turnover on Bone Strength and Pattern of Experimental Fractures of the Tibia in MiceNicolas Bonnet, Maude Gerbaix, Michael Ominsky, et al.Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|May 6, 2016
Finite Element Analysis of Denosumab Treatment Effects on Vertebral Strength in Ovariectomized Cynomolgus MonkeysDavid C Lee, Aurore Varela, Paul J Kostenuik, et al.Bone|March 31, 2004
Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized micePaul J Kostenuik, Brad Bolon, Sean Morony, et al.Bone|April 5, 2011
Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibodyPaul J Kostenuik, Susan Y Smith, Jacquelin Jolette, et al.Pageof 6